TerminatedPhase 3NCT01086852
Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery
Studying Congenital factor X deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bio Products Laboratory
- Principal Investigator
- Tim AldwinckleBio Products Laboratory
- Intervention
- FACTOR X(biological)
- Enrollment
- 4 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2011 – 2014
Study locations (7)
- University Of Texas Health Science Center, Gulf States Hemophilia and Thrombophilia Center 6655 Travis St, Houston, Texas, United States
- Unidad Coagulopatías, Congenitas, Edificio Dotacional, 1ra Planta Hospital Universito La Paz, Madrid, Spain
- Ege University School of Medicine, Departmant of Pediatric Hematology, Bornova, İzmir, Turkey (Türkiye)
- Istanbul University Cerrahpasa Medicine Faculty Department of Pediatric Hematology, Istanbul, Turkey (Türkiye)
- Department of Hematology, Royal Cornwall Hospital,, Truro, Cornwall, United Kingdom
- The Katherine Dormandy Haemophilia Centre and Thrombosis Unit, The Royal Free Hospital,Pond Street, Hampstead, London, United Kingdom
- Hammersmith Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01086852 on ClinicalTrials.gov